An Australian climate change agency has awarded a Madison energy business with a $275,000 grant to continue development of technologies that limit greenhouse gas emissions. The New South Wales Department of Environment and Climate Change awarded the technology climate action grant to BEST Energies for...
The recent controversy over GlaxoSmithKline's diabetes drug Avandia has once again put the Food & Drug Administration in Congressional crosshairs. In Part I of a MedTech Futures column on the FDA approval process, Dr. Ogan Gurel suggests that safety-minded FDA employees be taken more seriously. ...
Angel investments in early-stage Wisconsin companies topped $100 million last year, but the average size of the Wisconsin angel deal - $2.2 million - has at least one observer wondering if some angels are taking the place of venture investors in follow-up rounds. Just over...
Michael Rosen isn't often in book review mode, but he's come across a business book that's not only too good to put down, but provides a roadmap for the future of American biotech and healthcare. In this edition of Yer Biotech Blues, he praises author...
Until recently, it was assumed that NimbleGen would continue on with plans to raise up to $75 million in an initial public offering of stock. That was until the pharmaceutical giant Roche called and eventually agreed to pay $272.5 million for the privately held Madison...
Cutting taxes always works to stimulate economic growth, according to State Senator Ted Kanavas, and the Wisconsin Act 255 tax credit program is further proof. In this guest column, Kanavas implores the Legislature to keep that lesson in mind as a proposed expansion to the...
The Wisconsin Alumni Research Foundation has entered into global licensing agreements with Becton Dickinson and Stem Cell Technologies, Inc., allowing them to develop and commercialize growth media and tissue culture services used in embryonic stem cell research. The products are made possible by findings at...
Be aware and more than a little afraid when a member of Congress cites the world's dislike for America as a major reason to “reform” the U.S. patent system, according to columnist Tom Still. In this edition of Inside Wisconsin, Still says that's exactly what's...
Perscitus Biosciences will use a $250,000 loan from the Wisconsin Department of Commerce to further develop two promising scientific technologies., including one that selectively protects normal cells from the toxic effects of chemotherapy and radiation therapy. Both technologies have passed early proof-of-concept milestones. ...
NeoClone, a Madison biotechnology company, has landed a $750,000 federal contract to continue its research into a test for ovarian cancer, which is one of the most difficult forms of cancer to detect in its early stages. Ovarian cancer is the fifth leading cause of...